Gastroesophageal Reflux Clinical Trial
Official title:
Oesophageal Manometry and Ambulatory Reflux Monitoring Predictors of Clinical Outcomes After Anti-reflux Surgery
Gastro-oesophageal reflux disease (GORD) is a common condition, where acid from the stomach
leaks up into the oesophagus (gullet) and causes symptoms such as heartburn and an unpleasant
taste in the back of the mouth. GORD can often be controlled with self-help measures and
medication. Occasionally, surgery to correct the problem may be needed.
A laparoscopic fundoplication is a keyhole (laparoscopic) procedure which is a highly
effective treatment. Although reflux-related symptoms are absent or well controlled in over
85% of patients at 5 years after the operation, younger patients may have higher expectations
that such an operation would hopefully last decades.
Oesophageal physiology tests such as 24-hour catheter pH (potential of hydrogen) and
impedance involve passing a small tube into oesophagus via patients' nose to monitor the
presence of stomach content (acid or non-acid) in the oesophagus. The manometry test measures
the pressures and coordination of pressure activity within the oesophagus. Bravo™ wireless pH
monitoring uses a capsule that is attached to the oesophageal lining. These tests are often
used as part of a pre-operative evaluation before anti-reflux surgery (ARS).
Several measurements in these tests (also called parameters) could potentially anticipate
clinical outcomes following anti-reflux surgery. The evidence for parameters like duration of
acid exposure, number of reflux episodes and association with symptoms, pressures and
co-ordination of pressure activity in the oesophagus, came from studies which were not
designed in the most rigorous way to determine whether a cause-effect relation exists between
treatment and outcome.
This is a single centre, retrospective, observational study in which patients who had
pre-operative physiology testing and anti-reflux surgery at a tertiary centre in the last 10
years will be assessed for reflux symptoms and quality of life over the phone, based on three
validated questionnaires. The study is designed to evaluate correlations between oesophageal
physiology parameters and symptomatic response to ARS.
This is a single centre, retrospective, cross-sectional study on patients who had anti-reflux
surgery and pre-operative oesophageal physiology testing over 10 years. The investigators
anticipate the recruitment of up to 350 subjects over 18 months.
Eligible patients will be contacted over the phone and asked whether they would be interested
in joining the study. Candidates will be presented with details no less than the exact nature
of the study, the implications and constraints of the protocol. Subjects will be made aware
that no intervention will be made in this study, therefore taking part involves no risks or
side effects. If all questions that satisfy inclusion and exclusion criteria are answered
satisfactorily, and patients are happy to enter the study, participants will be consented
verbally over the phone. It will be stated that the participant is free to withdraw from the
study at any time for any reason without prejudice to future care, and with no obligation to
give the reason for withdrawal.
Once recruited the following assessments and interventions will take place:
1. Patients will be assessed based on the Reflux Disease Questionnaire (RDQ) which is
designed to assess the frequency and severity of heartburn, regurgitation and dyspeptic
symptoms. Response options are scaled as Likert-type with scores for and severity. RDQ
demonstrated validity and reliability in multiple languages and represents a viable
instrument for assessing symptom severity and response to treatment.
2. Patients will also be assessed based on The Reflux Symptoms Index (RSI) questionnaire
which evaluates the presence and severity of laryngopharyngeal reflux (LPR). RSI can be
completed in less than one minute. It is easily administered, highly reproducible and
demonstrated design- and criteria-based validity in multiple languages.
3. Participants will finally be evaluated based on the Gastroesophageal Reflux Disease
Health-Related Quality of Life (GORD-HRQL) questionnaire which is aimed at typical
reflux symptoms and impact on the daily living. The questionnaire can be easily given
over the phone in less than 2 minutes. GORD-HRQL has been validated and is a reliable
and practical tool in several languages.
4. Data recorded will include the standard components of pre-operative oesophageal pH
monitoring and high-resolution manometry, reflux symptoms scores, PPIs (proton pump
inhibitors) usage, post-operative physiology studies and re-do anti-reflux surgery.
5. Statistical analysis will involve multiple logistic regression and multiple linear
regression models. Sensitivity and specificity of each predictor will be measured using
the Receiver Operating Characteristic (ROC) curve analysis. A minimum of 350 patients
for 5 predictors will define our sample size.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05561179 -
Hyaluronic Acid in Patients With Gastroesophageal Reflux Disease
|
N/A | |
Withdrawn |
NCT02213887 -
Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications
|
Phase 4 | |
Completed |
NCT01946971 -
Lansoprazole in Preterm Infants With Gastroesophageal Reflux (GER)
|
Phase 1/Phase 2 | |
Recruiting |
NCT01825473 -
Study of Erythromycin in GER-Associated Apnea of the Newborn
|
N/A | |
Completed |
NCT00614536 -
Study of Changes in Reflux Symptoms and Reflux Finding Score According to Rabeprazole Treatment Period
|
Phase 4 | |
Completed |
NCT00365300 -
Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD)
|
Phase 3 | |
Completed |
NCT00373997 -
Esophageal and Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux
|
Phase 4 | |
Completed |
NCT00284908 -
Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00291746 -
Validation of RDQ Questionnaire
|
Phase 4 | |
Completed |
NCT01167543 -
Relationship and Pathophysiology of Gastroesophageal Reflux and Dental/Periodontal Disease
|
N/A | |
Completed |
NCT00215787 -
Investigation of the Association Between Nasal Polyposis and Extraesophageal Reflux Disease
|
N/A | |
Completed |
NCT00226044 -
Rectal and Oral Omeprazole Treatment of Reflux Disease in Infants.
|
Phase 3 | |
Completed |
NCT00567021 -
German PMS Trial (AWB) to Evaluate Therapy in Reflux Disease and NSAR-Symptoms
|
N/A | |
Completed |
NCT00141960 -
Famotidine in Subjects With Non-erosive Gastroesophageal Reflux Disease
|
Phase 2/Phase 3 | |
Completed |
NCT01048840 -
Natural History of Gastroesophageal Reflux (GER) in Children < 12 Years of Age
|
||
Completed |
NCT00181805 -
Natural History of Gastroesophageal Reflux (GER) in Children and Adolescents
|
||
Terminated |
NCT01281553 -
A Study of Cisapride in Patients With Symptomatic Gastro-Oesophageal Reflux Disease
|
Phase 4 | |
Completed |
NCT05486169 -
Gastroesophageal Reflux Disease After Laparoscopic Sleeve Gastrectomy
|
N/A | |
Completed |
NCT04034017 -
Gastroesophageal Reflux Disease Among College Students
|
||
Terminated |
NCT03226054 -
Determining Risk Factors for Successful PPI Weaning
|
N/A |